Welcome to BioArctic’s website. In order to optimize your use of our website we use cookies. If you want more information about our cookie policy, please read more here. By continuing, you agree to our use of cookies.
BioArctic Neuroscience AB today announced that the first patient in Sweden has been treated with BAN2401 in a clinical study aimed at patients with an early ...